What is HUMA's current stock price?

HUMA (Humacyte, Inc.) is currently trading at $1.05 with a market cap of $176.4M.

What sector is Humacyte, Inc. in?

Humacyte, Inc. (HUMA) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is HUMA a good stock to buy?

Analysts have a Buy consensus on HUMA with a price target of $3.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

HUMA Humacyte, Inc.

Healthcare

$1.05+2.94%ClosedMarket Cap: $176.4M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

17.87

P/S

87.50

EV/EBITDA

-1.73

DCF Value

$-0.02

FCF Yield

-58.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

-748.5%

Operating Margin

-5649.2%

Net Margin

-4840.8%

ROE

-2781.6%

ROA

-88.3%

ROIC

-117.7%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$495.0K	$-17.6M	$—
Q4 null	$467.0K	$-24.8M	$—
FY null	$2.0M	$-40.8M	$—
Q3 null	$753.0K	$-17.5M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$3.00

Target (Median)

$3.00

Target Range

$3.00 - $3.00

2 Strong Buy4 Buy1 Hold0 Sell0 Strong Sell

TD CowenBuy

2026-05-14

BTIGBuy

2026-05-13

D. Boral CapitalBuy

2026-04-28

BarclaysOverweight

2026-04-08

BenchmarkSpeculative Buy

2026-03-31

Trading Activity

Insider Trades

View All

Sebelius Kathleendirector

BuyWed May 20

Sander Dale A.officer: CFO and Chief Corp. Dev. Off

SellWed May 20

Parikh Shamik Jofficer: Chief Medical Officer

SellWed May 20

Constantino Michael T.director

BuyWed May 20

FRESENIUS MEDICAL CARE HOLDINGS INC /NY/

SellMon Dec 08

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

2.31

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Peers